Asean Bio-preparedness Meeting and Exercise, 2015

Bio-preparedness in Japan

Department of Immunology and Microbiology, National Defense Medical College

Manabu Kinoshita M.D, Ph.D

Department of Health Crisis Management, National Institute of Public Health

Tomoya Saito, MD, PhD



Today's Topics

- Bioterrorism in Japan and our preparedness
 Public health, Police, and Self Defense Force
- Pandemic diseases in Japan and our preparedness
 Swine Flu, Avian Flu (H5N1), Ebola virus disease
- Catastrophe (disaster) in Japan and our preparedness
 Blood substitutes (red blood cell substitute, platelet substitute)

Department of Immunology & Microbiology, National Defense Medical College Japan



Bioterrorism

Backgrounds

Attempt at biological attacks by Aum Shinrikyo
 April, 1990. Air spraying of botulinum toxin in Tokyo
 June 28, July 2, 1993. Kameido anthracis incident in Tokyo

These bio-terror attacks were not successful. (no victims)

• 9.11. attacks and Anthrax attack in U.S. (2001) Increasing threat of terrorism

Air spraying of anthrax bacteria in Tokyo





Department of Immunology & Microbiology, National Defense Medical College Japan



Actions/response against bioterrorism

Ministry of Health, Labour and Welfare (Public health)

• Stockpiling smallpox vaccine (2002~)

LC16m8 (Kaketsuken, Kumamoto, Japan) cell-cultured attenuated Smallpox vaccine





Headquarter of Ministry of Health, Labour and Welfare

 Amendment of Infectious Disease Control Act (2003-7)

Terrorist Attack Preparedness Action Plan (2004)

Security sectors demanded to establish a pathogen control system, because there was no such a regulation to ban terrorists to possess highly dangerous pathogens.

The pathogen control scheme was added to the Infectious Disease Control Act (2006)


Establishment of Civil Protection Act (2004) Cabinet


Legislation of a crisis management

NBC attacks were included in the scenarios of Civil Protection Plan


Department of Immunology & Microbiology, National Defense Medical College Japan














Actions

Ministry of Health, Labour and Welfare (Public health)

Medical countermeasures preparedness for pandemic flu in Japan

Anti-viral drugs

V Stockpiling Tamiflu® and Relenza® for 45% of Japanese population

Discussion on reducing stockpile is going.

∨ Conditional licensure for Avigan®

in case of novel flu resistant to current anti-virus



Vaccines

- V Stockpiling pre-pandemic vaccine for H5N1 (for 3 strains, 10 million dose/each)
- V Prototype cell-cultured vaccine has been licensed for early development of pandemic vaccine



Department of Immunology & Microbiology, National Defense Medical College Japan

Ebola outbreak in West Africa

Preparedness for Viral Hemorrhagic Fevers in Japan

- v Viral Hemorrhagic Fever is classified in the Category 1 infectious diseases under the Infectious Disease Control Act.
- Patients of Category 1 infectious diseases are to be hospitalized in specified or class 1 infectious disease hospitals, with negative pressured private wards.
 (specified infectious hospitals: 3, class 1 infectious hospitals: 45)
- Viral Hemorrhagic Fever is a quarantine diseases under the Quarantine Act and the patients are to be isolated and high risk contacts are to be quarantined strictly.



National Center for Global Health and Medicine (Specified Infectious Disease Hospital)



National Institute of Infectious Diseases

v We are not operating BSL4 laboratories but diagnosis capacity for Viral Hemorrhagic Fever is available in the National Institute of Infectious Diseases at BSL3 laboratory.

Government recently reached an agreement with local community in operating a BSL4 facility

Ebola outbreak in West Africa

Japan's response to outbreak of Ebola virus disease in West Africa

Japan supported activities related to Ebola outbreak financially, in-kind and in personnel.

- Total funding: USD 184 million
- Development and in-kind contribution
 - V Medical equipment, vehicles (ambulances), thermography cameras
 - V Portable Ebola virus test kit

Portable RT-LAMP assay device (Genie III) and specific primers developed in Nagasaki Univ. High specificity and sensitivity was shown by testing clinical samples in Guinea. Provided to Guinea on request in April 2015 for use intensive campaign.

V Anti-viral drug for Ebola virus

Avigan® provided for an emergency use and Toyama Chemical Co. has performed a clinical trial in Guinea.







Catastrophe in Japan and our preparedness

March 11, 2011. 2: 43 pm. Great East Japan Earthquake (M=9.0)

Twenty to thirty minutes later, huge tsunamis (max: 40 m; 131 ft high) attacked the Pacific coast of East Japan.

Tsunamis completely destroyed the coastal cities.

Approximately 20,000 people were killed or remain missing.





Almost all structures were destroyed and many ships were loft up in the midtown.

Department of Immunology & Microbiology, National Defense Medical College Japan



